<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6939334/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>US FDA-approved monoclonal antibody on the market</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">mAb</th>
   <th colspan="1" rowspan="1" id="0-1-.">Brand name</th>
   <th colspan="1" rowspan="1" id="0-2-.">Company</th>
   <th colspan="1" rowspan="1" id="0-3-.">Target</th>
   <th colspan="1" rowspan="1" id="0-4-.">Format</th>
   <th colspan="1" rowspan="1" id="0-5-.">Technology</th>
   <th colspan="1" rowspan="1" id="0-6-.">Indication 
    <sup>&amp;</sup>
   </th>
   <th colspan="1" rowspan="1" id="0-7-.">US 
    <sup>#</sup> Approval 
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>Muromonab-CD3</td>
   <td>Orthoclone OKT3</td>
   <td>Centocor Ortho Biotech Products LP.</td>
   <td>CD3</td>
   <td>Murine IgG2a</td>
   <td>Hybridoma/Janssen Biotech, Inc</td>
   <td>Kidney transplant rejection</td>
   <td>1986*</td>
  </tr>
  <tr>
   <td>Abciximab</td>
   <td>Reopro</td>
   <td>Centocor Inc./Eli Lilly/Janssen Biotech Inc.</td>
   <td>GPIIb/IIIa</td>
   <td>Chimeric IgG1 Fab</td>
   <td>Hybridoma</td>
   <td>Prevention of blood clots in angioplasty</td>
   <td>1994</td>
  </tr>
  <tr>
   <td>Rituximab</td>
   <td>MabThera, Rituxan</td>
   <td>Biogen Inc./Roche, F. Hoffmann-La Roche Ltd./Genentech Inc.</td>
   <td>CD20</td>
   <td>Chimeric IgG1</td>
   <td>Hybridoma</td>
   <td>Non-Hodgkin lymphoma</td>
   <td>1997</td>
  </tr>
  <tr>
   <td>Palivizumab</td>
   <td>Synagis</td>
   <td>MedImmune/AbbVie Inc.</td>
   <td>RSV</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Prevention of respiratory syncytial virus infection</td>
   <td>1998</td>
  </tr>
  <tr>
   <td>Infliximab</td>
   <td>Remicade</td>
   <td>Janssen Biotech Inc.</td>
   <td>TNFα</td>
   <td>Chimeric IgG1</td>
   <td>Hybridoma</td>
   <td>Crohn’s disease</td>
   <td>1998</td>
  </tr>
  <tr>
   <td>Trastuzumab</td>
   <td>Herceptin</td>
   <td>Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc.</td>
   <td>HER2</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Breast cancer</td>
   <td>1998</td>
  </tr>
  <tr>
   <td>Alemtuzumab</td>
   <td>Campath, Lemtrada</td>
   <td>Berlex Inc./Genzyme Corp./Millennium Pharmaceuticals Inc.</td>
   <td>CD52</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Chronic myeloid leukemia</td>
   <td>2001</td>
  </tr>
  <tr>
   <td>Adalimumab</td>
   <td>Humira</td>
   <td>AbbVie Inc.</td>
   <td>TNFα</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Rheumatoid arthritis</td>
   <td>2002</td>
  </tr>
  <tr>
   <td>Ibritumomab tiuxetan</td>
   <td>Zevalin</td>
   <td>Biogen Inc./Schering AG/Spectrum Pharmaceuticals Inc.</td>
   <td>CD20</td>
   <td>Murine IgG1</td>
   <td>Hybridoma</td>
   <td>Non-Hodgkin lymphoma</td>
   <td>2002</td>
  </tr>
  <tr>
   <td>Omalizumab</td>
   <td>Xolair</td>
   <td>Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc./Novartis Pharmaceuticals Corp./Tanox Inc.</td>
   <td>IgE</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Asthma</td>
   <td>2003</td>
  </tr>
  <tr>
   <td>Cetuximab</td>
   <td>Erbitux</td>
   <td>Bristol-Myers Squibb/Merck &amp; Co. Inc./Eli Lilly/ImClone Systems Inc.</td>
   <td>EGFR</td>
   <td>Chimeric IgG1</td>
   <td>Hybridoma</td>
   <td>Colorectal cancer</td>
   <td>2004</td>
  </tr>
  <tr>
   <td>Bevacizumab</td>
   <td>Avastin</td>
   <td>Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc.</td>
   <td>VEGF-A</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Colorectal cancer</td>
   <td>2004</td>
  </tr>
  <tr>
   <td>Natalizumab</td>
   <td>Tysabri</td>
   <td>Biogen Inc./Elan Pharmaceuticals International, Ltd.</td>
   <td>ITGA4</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>Multiple sclerosis</td>
   <td>2004</td>
  </tr>
  <tr>
   <td>Panitumumab</td>
   <td>Vectibix</td>
   <td>Amgen</td>
   <td>EGFR</td>
   <td>Human IgG2</td>
   <td>Transgenic mice</td>
   <td>Colorectal cancer</td>
   <td>2006</td>
  </tr>
  <tr>
   <td>Ranibizumab</td>
   <td>Lucentis</td>
   <td>Roche, F. Hoffmann-La Roche Ltd./Genentech Inc./Novartis Pharmaceuticals Corp.</td>
   <td>VEGF-A</td>
   <td>Humanized IgG1 Fab</td>
   <td>Hybridoma</td>
   <td>Macular degeneration</td>
   <td>2006</td>
  </tr>
  <tr>
   <td>Eculizumab</td>
   <td>Soliris</td>
   <td>Alexion Pharmaceuticals Inc.</td>
   <td>C5</td>
   <td>Humanized IgG2/4</td>
   <td>Hybridoma</td>
   <td>Paroxysmal nocturnal hemoglobinuria</td>
   <td>2007</td>
  </tr>
  <tr>
   <td>Certolizumab pegol</td>
   <td>Cimzia</td>
   <td>Celltech, UCB.</td>
   <td>TNFα</td>
   <td>Humanized Fab, pegylated</td>
   <td>Hybridoma</td>
   <td>Crohn’s disease</td>
   <td>2008</td>
  </tr>
  <tr>
   <td>Ustekinumab</td>
   <td>Stelara</td>
   <td>Medarex/Centocor Ortho Biotech Inc./Janssen Biotech Inc.</td>
   <td>IL-12/23</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Psoriasis</td>
   <td>2009</td>
  </tr>
  <tr>
   <td>Canakinumab</td>
   <td>Ilaris</td>
   <td>Novartis Pharmaceuticals Corp.</td>
   <td>IL-1β</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Muckle-Wells syndrome</td>
   <td>2009</td>
  </tr>
  <tr>
   <td>Golimumab</td>
   <td>Simponi</td>
   <td>Centocor Ortho Biotech Inc./Janssen Biotech Inc.</td>
   <td>TNFα</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Rheumatoid and psoriatic arthritis, ankylosing spondylitis</td>
   <td>2009</td>
  </tr>
  <tr>
   <td>Ofatumumab</td>
   <td>Arzerra</td>
   <td>Genmab A/S /GlaxoSmithKline /Novartis.</td>
   <td>CD20</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Chronic lymphocytic leukemia</td>
   <td>2009</td>
  </tr>
  <tr>
   <td>Tocilizumab</td>
   <td>RoActemra, Actemra</td>
   <td>Chugai Pharmaceutical Co., Ltd./Roche, F. Hoffmann-La Roche. Ltd./Genentech Inc.</td>
   <td>IL-6R</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Rheumatoid arthritis</td>
   <td>2010</td>
  </tr>
  <tr>
   <td>Denosumab</td>
   <td>Xgeva, Prolia</td>
   <td>Amgen</td>
   <td>RANKL</td>
   <td>Human IgG2</td>
   <td>Transgenic mice</td>
   <td>Bone loss</td>
   <td>2010</td>
  </tr>
  <tr>
   <td>Belimumab</td>
   <td>Benlysta</td>
   <td>GlaxoSmithKline /Human Genome Sciences Inc.</td>
   <td>BLyS</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Systemic lupus erythematosus</td>
   <td>2011</td>
  </tr>
  <tr>
   <td>Ipilimumab</td>
   <td>Yervoy</td>
   <td>Bristol-Myers Squibb/Medarex</td>
   <td>CTLA-4</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Metastatic melanoma</td>
   <td>2011</td>
  </tr>
  <tr>
   <td>Brentuximab vedotin</td>
   <td>Adcetris</td>
   <td>Seattle genetics Inc./Takeda Pharmaceutical Co., Ltd.</td>
   <td>CD30</td>
   <td>Chimeric IgG1; ADC</td>
   <td>Hybridoma</td>
   <td>Hodgkin lymphoma, systemic anaplastic large cell lymphoma</td>
   <td>2011</td>
  </tr>
  <tr>
   <td>Pertuzumab</td>
   <td>Perjeta</td>
   <td>Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc.</td>
   <td>HER2</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Breast Cancer</td>
   <td>2012</td>
  </tr>
  <tr>
   <td>Trastuzumab emtansine</td>
   <td>Kadcyla</td>
   <td>Roche, F. Hoffmann-La Roche Ltd./Genentech Inc./ImmunoGen Inc.</td>
   <td>HER2</td>
   <td>Humanized IgG1; ADC</td>
   <td>Hybridoma</td>
   <td>Breast cancer</td>
   <td>2012</td>
  </tr>
  <tr>
   <td>Raxibacumab</td>
   <td>Abthrax</td>
   <td>GlaxoSmithKline /Human Genome Sciences Inc. (HGSI)</td>
   <td>
    <i>B. anthrasis</i> PA 
   </td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Anthrax infection</td>
   <td>2012</td>
  </tr>
  <tr>
   <td>Obinutuzumab</td>
   <td>Gazyva, Gazyvaro</td>
   <td>Biogen Inc./Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc.</td>
   <td>CD20</td>
   <td>Humanized IgG1 Glycoengineered</td>
   <td>Hybridoma</td>
   <td>Chronic lymphocytic leukemia</td>
   <td>2013</td>
  </tr>
  <tr>
   <td>Siltuximab</td>
   <td>Sylvant</td>
   <td>Centocor Inc./Janssen Biotech Inc./Janssen-Cilag International NV</td>
   <td>IL-6</td>
   <td>Chimeric IgG1</td>
   <td>Hybridoma</td>
   <td>Castleman disease</td>
   <td>2014</td>
  </tr>
  <tr>
   <td>Ramucirumab</td>
   <td>Cyramza</td>
   <td>Eli Lilly/ImClone Systems Inc.</td>
   <td>VEGFR2</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Gastric cancer</td>
   <td>2014</td>
  </tr>
  <tr>
   <td>Vedolizumab</td>
   <td>Entyvio</td>
   <td>Genentech Inc./Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals U.S.A. Inc.</td>
   <td>α4β7 integrin</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Ulcerative colitis, Crohn disease</td>
   <td>2014</td>
  </tr>
  <tr>
   <td>Blinatumomab</td>
   <td>Blincyto</td>
   <td>Amgen</td>
   <td>CD19, CD3</td>
   <td>Murine bispecific tandem scFv</td>
   <td>Hybridoma</td>
   <td>Acute lymphoblastic leukemia</td>
   <td>2014</td>
  </tr>
  <tr>
   <td>Nivolumab</td>
   <td>Opdivo</td>
   <td>Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd.</td>
   <td>PD-1</td>
   <td>Human IgG4</td>
   <td>Transgenic mice</td>
   <td>Melanoma, non-small cell lung cancer</td>
   <td>2014</td>
  </tr>
  <tr>
   <td>Pembrolizumab</td>
   <td>Keytruda</td>
   <td>Merck &amp; Co. Inc.</td>
   <td>PD-1</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>Melanoma</td>
   <td>2014</td>
  </tr>
  <tr>
   <td>Idarucizumab</td>
   <td>Praxbind</td>
   <td>Boehringer Ingelheim Pharmaceuticals</td>
   <td>Dabigatran</td>
   <td>Humanized Fab</td>
   <td>Hybridoma</td>
   <td>Reversal of dabigatran-induced anticoagulation</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Necitumumab</td>
   <td>Portrazza</td>
   <td>Eli Lilly/ImClone Systems Inc.</td>
   <td>EGFR</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Non-small cell lung cancer</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Dinutuximab</td>
   <td>Unituxin</td>
   <td>United Therapeutics Corporation</td>
   <td>GD2</td>
   <td>Chimeric IgG1</td>
   <td>Hybridoma</td>
   <td>Neuroblastoma</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Secukinumab</td>
   <td>Cosentyx</td>
   <td>Novartis Pharmaceuticals Corp.</td>
   <td>IL-17α</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Psoriasis</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Mepolizumab</td>
   <td>Nucala</td>
   <td>Centocor Inc./GlaxoSmithKline</td>
   <td>IL-5</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Severe eosinophilic asthma</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Alirocumab</td>
   <td>Praluent</td>
   <td>Regeneron Pharmaceuticals Inc./Sanofi.</td>
   <td>PCSK9</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>High cholesterol</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Evolocumab</td>
   <td>Repatha</td>
   <td>Amgen/Amgen Astellas BioPharma K.K.</td>
   <td>PCSK9</td>
   <td>Human IgG2</td>
   <td>Transgenic mice</td>
   <td>High cholesterol</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Daratumumab</td>
   <td>Darzalex</td>
   <td>Genmab A/S/Janssen Biotech Inc.</td>
   <td>CD38</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Multiple myeloma</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Elotuzumab</td>
   <td>Empliciti</td>
   <td>Bristol-Myers Squibb/AbbVie Inc.</td>
   <td>SLAMF7</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Multiple myeloma</td>
   <td>2015</td>
  </tr>
  <tr>
   <td>Ixekizumab</td>
   <td>Taltz</td>
   <td>Eli Lilly</td>
   <td>IL-17α</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>Psoriasis</td>
   <td>2016</td>
  </tr>
  <tr>
   <td>Reslizumab</td>
   <td>Cinqaero, Cinqair</td>
   <td>Celltech, UCB/Schering-Plough/Teva Pharmaceutical Industries, Ltd.</td>
   <td>IL-5</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>Asthma</td>
   <td>2016</td>
  </tr>
  <tr>
   <td>Olaratumab</td>
   <td>Lartruvo</td>
   <td>Eli Lilly/ImClone Systems Inc.</td>
   <td>PDGFRα</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Soft tissue sarcoma</td>
   <td>2016</td>
  </tr>
  <tr>
   <td>Bezlotoxumab</td>
   <td>Zinplava</td>
   <td>Merck &amp; Co. Inc.</td>
   <td>
    <i>Clostridium difficile</i> enterotoxin B 
   </td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Prevention of 
    <i>Clostridium difficile</i> infection recurrence 
   </td>
   <td>2016</td>
  </tr>
  <tr>
   <td>Atezolizumab</td>
   <td>Tecentriq</td>
   <td>Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc.</td>
   <td>PD-L1</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Bladder cancer</td>
   <td>2016</td>
  </tr>
  <tr>
   <td>Obiltoxaximab</td>
   <td>Anthim</td>
   <td>Elusys Therapeutics Inc.</td>
   <td>
    <i>B. anthrasis</i> PA 
   </td>
   <td>Chimeric IgG1</td>
   <td>Hybridoma</td>
   <td>Prevention of inhalational anthrax</td>
   <td>2016</td>
  </tr>
  <tr>
   <td>Inotuzumab ozogamicin</td>
   <td>Besponsa</td>
   <td>Wyeth Pharmaceuticals/Pfizer.</td>
   <td>CD22</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>Acute lymphoblastic leukemia</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Brodalumab</td>
   <td>Siliq, Lumicef</td>
   <td>MedImmune/Amgen/Kyowa Hakko Kirin /AstraZeneca/Valeant Pharmaceuticals International Inc.</td>
   <td>IL-17R</td>
   <td>Human IgG2</td>
   <td>Transgenic mice</td>
   <td>Plaque psoriasis</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Guselkumab</td>
   <td>Tremfya</td>
   <td>MorphoSys/Janssen Biotech Inc.</td>
   <td>IL-23 p19</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Plaque psoriasis</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Dupilumab</td>
   <td>Dupixent</td>
   <td>Regeneron Pharmaceuticals Inc./Sanofi</td>
   <td>IL-4Rα</td>
   <td>Human IgG4</td>
   <td>Transgenic mice</td>
   <td>Atopic dermatitis</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Sarilumab</td>
   <td>Kevzara</td>
   <td>Regeneron Pharmaceuticals Inc./Sanofi</td>
   <td>IL-6R</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Rheumatoid arthritis</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Avelumab</td>
   <td>Bavencio</td>
   <td>Merck Serono International S.A./Pfizer</td>
   <td>PD-L1</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Merkel cell carcinoma</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Ocrelizumab</td>
   <td>Ocrevus</td>
   <td>Biogen Inc./Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc./SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.</td>
   <td>CD20</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Multiple sclerosis</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Emicizumab</td>
   <td>Hemlibra</td>
   <td>Chugai Pharmaceutical Co., Ltd./Roche, F. Hoffmann-La Roche, Ltd.</td>
   <td>Factor IXa, X</td>
   <td>Humanized IgG4, bispecific</td>
   <td>Hybridoma</td>
   <td>Hemophilia A</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Benralizumab</td>
   <td>Fasenra</td>
   <td>MedImmune/Kyowa Hakko Kirin/AstraZeneca</td>
   <td>IL-5Rα</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Asthma</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Gemtuzumab ozogamicin</td>
   <td>Mylotarg</td>
   <td>Pfizer</td>
   <td>CD33</td>
   <td>Humanized IgG4; ADC</td>
   <td>Hybridoma</td>
   <td>Acute myeloid leukemia</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Durvalumab</td>
   <td>Imfinzi</td>
   <td>MedImmune/AstraZeneca</td>
   <td>PD-L1</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>Bladder cancer</td>
   <td>2017</td>
  </tr>
  <tr>
   <td>Burosumab</td>
   <td>Crysvita</td>
   <td>Kyowa Hakko Kirin/Ultragenyx Pharmaceutical Inc.</td>
   <td>FGF23</td>
   <td>Human IgG1</td>
   <td>Transgenic mice</td>
   <td>X-linked hypophosphatemia</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Lanadelumab</td>
   <td>Takhzyro</td>
   <td>Dyax Corp.</td>
   <td>Plasma kallikrein</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Hereditary angioedema attacks</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Mogamulizumab</td>
   <td>Poteligeo</td>
   <td>Kyowa Hakko Kirin</td>
   <td>CCR4</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Mycosis fungoides or Sézary syndrome</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Erenumab</td>
   <td>Aimovig</td>
   <td>Novartis</td>
   <td>CGRPR</td>
   <td>Human IgG2</td>
   <td>Transgenic mice</td>
   <td>Migraine prevention</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Galcanezumab</td>
   <td>Emgality</td>
   <td>Eli Lilly</td>
   <td>CGRP</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>Migraine prevention</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Tildrakizumab</td>
   <td>Ilumya</td>
   <td>Merck &amp; Co. Inc./Sun Pharmaceutical Industries, Ltd.</td>
   <td>IL-23 p19</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Plaque psoriasis</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Cemiplimab</td>
   <td>Libtayo</td>
   <td>Regeneron Pharmaceuticals Inc.</td>
   <td>PD-1</td>
   <td>Human mAb</td>
   <td>Transgenic mice</td>
   <td>Cutaneous squamous cell carcinoma</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Emapalumab</td>
   <td>Gamifant</td>
   <td>NovImmmune</td>
   <td>IFNγ</td>
   <td>Human IgG1</td>
   <td>Phage display</td>
   <td>Primary hemophagocytic lymphohistiocytosis</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Fremanezumab</td>
   <td>Ajovy</td>
   <td>Teva Pharmaceutical Industries, Ltd.</td>
   <td>CGRP</td>
   <td>Humanized IgG2</td>
   <td>Hybridoma</td>
   <td>Migraine prevention</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Ibalizumab</td>
   <td>Trogarzo</td>
   <td>Taimed Biologics Inc./Theratechnologies Inc.</td>
   <td>CD4</td>
   <td>Humanized IgG4</td>
   <td>Hybridoma</td>
   <td>HIV infection</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Moxetumomab pasudodox</td>
   <td>Lumoxiti</td>
   <td>MedImmune/AstraZeneca</td>
   <td>CD22</td>
   <td>Murine IgG1 dsFv</td>
   <td>Phage display</td>
   <td>Hairy cell leukemia</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Ravulizumab</td>
   <td>Ultomiris</td>
   <td>Alexion Pharmaceuticals Inc.</td>
   <td>C5</td>
   <td>humanized IgG2/4</td>
   <td>Hybridoma</td>
   <td>Paroxysmal nocturnal hemoglobinuria</td>
   <td>2018</td>
  </tr>
  <tr>
   <td>Caplacizumab</td>
   <td>Cablivi</td>
   <td>Ablynx</td>
   <td>von Willebrand factor</td>
   <td>
    <p>Humanized</p>
    <p>Nanobody</p>
   </td>
   <td>Hybridoma</td>
   <td>Acquired thrombotic thrombocytopenic purpura</td>
   <td>2019</td>
  </tr>
  <tr>
   <td>Romosozumab</td>
   <td>Evenity</td>
   <td>Amgen/UCB</td>
   <td>Sclerostin</td>
   <td>Humanized IgG2</td>
   <td>Hybridoma</td>
   <td>Osteoporosis in postmenopausal women at increased risk of fracture</td>
   <td>2019</td>
  </tr>
  <tr>
   <td>Risankizumab</td>
   <td>Skyrizi</td>
   <td>Boehringer Ingelheim Pharmaceuticals/ AbbVie Inc.</td>
   <td>IL-23 p19</td>
   <td>Humanized IgG1</td>
   <td>Hybridoma</td>
   <td>Plaque psoriasis</td>
   <td>2019</td>
  </tr>
  <tr>
   <td>Polatuzumab vedotin</td>
   <td>Polivy</td>
   <td>Roche, F. Hoffmann-La Roche, Ltd.</td>
   <td>CD79β</td>
   <td>Humanized IgG1 ADC</td>
   <td>Hybridoma</td>
   <td>Diffuse large B-cell lymphoma</td>
   <td>2019</td>
  </tr>
  <tr>
   <td>Brolucizumab</td>
   <td>Beovu</td>
   <td>Novartis Pharmaceuticals Corp.</td>
   <td>VEGF-A</td>
   <td>Humanized scFv</td>
   <td>Hybridoma 
    <sup>$</sup>
   </td>
   <td>Macular degeneration</td>
   <td>2019</td>
  </tr>
  <tr>
   <td>Crizanlizumab</td>
   <td>Adakveo</td>
   <td>Novartis Pharmaceuticals Corp.</td>
   <td>P-selectin</td>
   <td>Humanized IgG2</td>
   <td>Hybridoma</td>
   <td>Sickle cell disease</td>
   <td>2019</td>
  </tr>
 </tbody>
 <tfoot>
  <p>*Marketing end date on July 30th, 2011</p>
  <p>
   <sup>#</sup>Year of the first US FDA approval 
  </p>
  <p>
   <sup>&amp;</sup>Indication of the first US FDA approval 
  </p>
  <p>
   <sup>$</sup>Rabbit hybridoma technology 
  </p>
 </tfoot>
</table>
